Company Overview and News

 
China Cord Blood (CO) Q3 2018 Results - Earnings Call Transcript

2018-02-27 seekingalpha
China Cord Blood Corporation (NYSE:CO) Q3 2018 Earnings Conference Call February 27, 2018 8:00 AM ET

2
Week In Review: Tsinghua University Invests $276 Million In Cambridge U.K. Biohub

2018-02-11 seekingalpha
Tsinghua University Holdings (TUS) of Beijing will invest $276 million to build a new biohub in the UK's Cambridge Science Park. The biohub will be a joint venture between TUS and Trinity College, Cambridge, the owner of the park. The money will build five new buildings, comprising 350,000 square feet. This includes a state-of-the-art biohub, which will provide labs and offices for early stage companies working on a wide range of healthcare technologies, including non-invasive diagnostics, new drugs, novel surgical techniques, and new home-monitoring technologies.

 
China Cord Blood's (CO) Management on Q2 2018 Results - Earnings Call Transcript

2017-11-21 seekingalpha
Welcome everyone to China Cord Blood Corporation Earnings Conference Call for the Second Quarter of Fiscal 2018. All participants' lines will be placed on mute during the presentation after which there will be a question-and-answer session. This conference is being recorded.

 
Golden Meditech Announces FY2016/2017 Annual Results

2017-06-28 devicespace
Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces today its annual results for the year ended 31 March 2017 (the "Year" or "FY2016/2017").

 
China Cord Blood (CO) Q4 2017 Results - Earnings Call Transcript

2017-06-22 seekingalpha
Welcome everyone to China Cord Blood Corporation's Earnings Conference Call for the Fourth Quarter and Full year of Fiscal 2017. All participants' lines will be placed on mute during the presentation after which there will be a question-and-answer session.

 
Golden Meditech Announces The Close Of The Voluntary Conditional Cash Offer And Remains Public

2017-04-10 devicespace
HONG KONG, April 10, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") closed on 10 April 2017.

 
Golden Meditech Announces the Close of the Voluntary Conditional Cash Offer and Remains Public

2017-04-10 prnewswire
HONG KONG, April 10, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") closed on 10 April 2017.

 
Golden Meditech Announces The Condition To The Voluntary Conditional Cash Offer Has Been Satisfied

2017-03-15 devicespace
HONG KONG, March 15, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the shareholding ratio condition to the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") has been satisfied, as a result, the voluntary conditional cash offer is now unconditional.

 
China Cord Blood (CO) Q3 2017 Results - Earnings Call Transcript

2017-02-27 seekingalpha
Welcome everyone to China Cord Blood Corporation's Earnings Conference Call for the Third Quarter of Fiscal 2017. Today's conference is being recorded. All participants' lines will be placed on mute during the presentation after which there will be a question-and-answer session.

 
China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2017

2017-02-24 prnewswire
HONG KONG, Feb. 24, 2017 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal year 2017 ended December 31, 2016.

 
Golden Meditech To Sell Its Equity Interest In China Cord Blood For Cash Consideration Of RMB5.764 Billion

2016-12-30 devicespace
HONG KONG, Dec. 30, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that it entered into a sale and purchase agreement with Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership) 1 ("Yingpeng Huikang Fund" or the "Purchaser") on 30 December 2016 regarding the disposal of the Company's entire equity stake in China Cord Blood Corporation ("CCBC") which represents 65.

 
Golden Meditech to Sell 65.4% Stake in China Cord Blood for $0.83B

2016-12-30 genengnews
Advances in Genome Sequencing, Pharmacogenomics, Gene Editing, and Biometric Wearables Will Provide New Pathways to Better Health

 
CORRECTED-BRIEF-Golden Meditech to sell its equity interest in China Cord Blood Corp

2016-12-30 feeds.reuters
(Corrects headline to "... to sell its equity interest in China Cord Blood Corp", from ".... to sell its equity interest in China")

 
CORRECTED-BRIEF-Golden Meditech to sell its equity interest in China Cord Blood Corp

2016-12-30 feeds.reuters
(Corrects headline to "... to sell its equity interest in China Cord Blood Corp", from ".... to sell its equity interest in China")

 
Golden Meditech to Sell its equity Interest in China Cord Blood Corporation for Cash Consideration of RMB5.764 Billion

2016-12-30 prnewswire
HONG KONG, Dec. 30, 2016 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces that it entered into a sale and purchase agreement with Nanjing Yingpeng Huikang Medical Industry Investment Partnership (Limited Partnership) 1 ("Yingpeng Huikang Fund" or the "Purchaser") on 30 December 2016 regarding the disposal of the Company's entire equity stake in China Cord Blood Corporation ("CCBC") which represents 65.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...